Science
Overview
Microbion’s innovative technology is focused on the development of a new class of antimicrobial compounds designed to address serious diseases, including resistant and difficult-to-treat infections, as well as conditions characterized by chronic or dysregulated inflammation. Among these compounds, pravibismane has demonstrated robust antibacterial activity against a broad spectrum of Gram-negative and Gram-positive bacteria, including their associated biofilms.
Biofilms are complex microbial communities that are frequently implicated in persistent infections and are notoriously unresponsive to conventional antibiotic therapies. By effectively targeting both planktonic bacteria and biofilm-associated pathogens, Microbion’s compounds offer a promising solution to a major clinical challenge.
In addition to its antimicrobial properties, pravibismane has exhibited potent anti-inflammatory and immunomodulatory effects. This unique combination of broad-spectrum antimicrobial, anti-biofilm, and immunomodulatory activities positions pravibismane as a potential first-in-class and best-in-class therapeutic candidate. Microbion’s approach represents an innovative clinical strategy for the treatment of a wide range of challenging and serious diseases.